Table 4 Patient outcomes
From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
Patient | Diagnosis | PD at entry | Prior chemo | Prior surgery | Prior XRT | Chemo lines (n) | PFS (months) | OS (months) | Best protocol response |
|---|---|---|---|---|---|---|---|---|---|
1 | NET1 | 1 | 1 | 0 | 0 | 1 | 2.1 | 13.5 | PD |
2 | NET | 1 | 0 | 0 | 0 | 0 | 0.8 | 2.3 | PD |
3 | MTC2 | 0 | 1 | 1 | 1 | 4 | 14.2 | 93.3 | SD |
4 | MTC | 0 | 1 | 1 | 1 | 4 | 2.3 | 93.3 | SD |
5 | MTC | 0 | 1 | 1 | 1 | 2 | 7.4 | 66.7 | SD |
6 | MTC | 0 | 1 | 1 | 1 | 3 | 0.5 | 4.1 | PD |
7 | MTC | 1 | 1 | 1 | 1 | 1 | 2.3 | 20.3 | PD |
8 | MTC | 1 | 1 | 1 | 1 | 3 | 2.2 | 7.1 | PD |
9 | NET | 1 | 1 | 0 | 1 | 3 | 0.5 | 0.5 | Death |
10 | ACC3 | 1 | 1 | 1 | 0 | 1 | 6.4 | 17.5 | MR |
11 | MTC | 0 | 0 | 1 | 1 | 0 | 7.7 | 88.6 | PD |
12 | ACC | 1 | 1 | 1 | 1 | 5 | 2.4 | 2.4 | Death |
13 | TCC4 | 1 | 1 | 1 | 0 | 6 | 2.6 | 9.1 | PD |
14 | ACC | 1 | 1 | 1 | 0 | 2 | 8.8 | 39.5 | PR |
15 | MTC | 0 | 0 | 1 | 0 | 0 | 6.3 | 82.0 | SD |
16 | ACC | 1 | 1 | 1 | 0 | 2 | 1.6 | 80.7 | PD |
17 | ACC | 1 | 0 | 1 | 0 | 0 | 1.7 | 79.5 | PD |
18 | Melanoma | 1 | 1 | 1 | 1 | 1 | 2.1 | 7.8 | PD |
19 | ACC | 1 | 1 | 1 | 0 | 2 | 2.1 | 13.4 | PD |
20 | ACC | 1 | 1 | 0 | 0 | 1 | 2.0 | 18.6 | PD |